Study on Tafasitamab and Lenalidomide as First Treatment for Residual Large B Cell Lymphoma

Inclusion Criteria

• Have a confirmed diagnosis of large B-cell lymphoma, including types like diffuse large B-cell lymphoma and others.
• Be 18 years or older.
• Be able to understand the study details and agree to follow all procedures and visits.
• Be willing to sign a consent form to participate.
• Have measurable disease on a PET/CT scan taken between 21 and 60 days after receiving CAR-T therapy with axicabtagene-ciloleucel.
• Have a performance status score of 0 to 2, indicating good overall health.
• Have adequate organ and bone marrow function.
• Have good liver and kidney function.
• Have an oxygen saturation level above 92% on room air.
• Women who can become pregnant must avoid pregnancy starting 4 weeks before and continuing through the study and for 4 weeks after, using two reliable birth control methods or abstaining from sex.

Exclusion Criteria

• Have received any experimental treatment within 4 weeks before the screening visit.
• Have cancer cells in the cerebrospinal fluid, brain metastases, or active central nervous system lymphoma after CAR T cell therapy.
• Have a history of central nervous system disorders like seizures or strokes.
• Have an uncontrolled infection requiring IV treatment.
• Have heart involvement with lymphoma.
• Have had a symptomatic blood clot in the lungs within 6 months before joining the study.
• Have a known primary immune deficiency.
• Have a history of autoimmune diseases requiring treatment in the last 2 years.
• Have had severe allergic reactions to lenalidomide or tafasitamab.
• Have any medical condition that might interfere with the study as determined by the doctor.